- Stocks
- Pharma & Healthcare
- CORONA Remedies
CORONA Remedies share price
NSE: CORONAPharma & HealthcareDrug Manufacturers - General
CORONA Remedies at a glance
CORONA Remedies (NSE: CORONA) closed at ₹2,024.70 on 22 Oct 2026, down 0.26% on the day. With a market capitalisation of ₹12,500 Cr, it ranks 493rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 66.8× trailing earnings, against a return on equity of 24.8% in FY26. Its 52-week range is ₹1,336.60 (23 Dec 2025) to ₹2,292.40 (15 Sep 2026); the last close is 11.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹422 Cr (+21.9% year on year) and net profit ₹60 Cr (+29.6%), on a consolidated basis. Promoters held 69.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹12,500 CrRank 493 on NSE
- P/E (trailing)
- 66.8×
- Price to book
- 12.74×FY26
- EPS (TTM)
- ₹32.54to Q1 FY27
- ROE
- 24.8%FY26
- ROCE
- 31.5%FY26
- Debt to equity
- 0.19FY26
- Net profit margin
- 13.2%FY26
- Book value / share
- ₹122.12FY26
- Dividend payout
- 24.2%FY26
- 52-week high
- ₹2,292.4015 Sep 2026
- 52-week low
- ₹1,336.6023 Dec 2025
- RSI (14-day)
- 43.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.26% | −1.6% | −8.1% | −0.8% | — |
CORONA Remedies quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹298 Cr | ₹294 Cr | ₹347 Cr | ₹361 Cr | ₹342 Cr | ₹353 Cr | ₹422 Cr |
| Revenue YoY | — | — | — | — | +15.0% | +20.2% | +21.9% |
| Net profit | ₹45 Cr | ₹31 Cr | ₹46 Cr | ₹52 Cr | ₹41 Cr | ₹45 Cr | ₹60 Cr |
| Net profit YoY | — | — | — | — | −7.9% | +44.6% | +29.6% |
| Net margin | 15.0% | 10.7% | 13.4% | 14.4% | 12.0% | 12.8% | 14.2% |
| EPS | ₹7.35 | ₹5.16 | ₹7.55 | ₹8.55 | ₹6.75 | ₹7.41 | ₹9.83 |
CORONA Remedies financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹884 Cr | ₹1,014 Cr | ₹1,196 Cr | — |
| Operating profit | ₹111 Cr | ₹118 Cr | ₹198 Cr | — |
| Net profit | ₹85 Cr | ₹91 Cr | ₹149 Cr | — |
| EPS (₹) | ₹15.00 | ₹15.00 | ₹24.00 | — |
| Cash from operations | ₹103 Cr | ₹157 Cr | ₹191 Cr | — |
| Total debt | ₹0 Cr | ₹67 Cr | ₹16 Cr | ₹0 Cr |
| Shareholders' equity | ₹409 Cr | ₹480 Cr | ₹606 Cr | ₹747 Cr |
CORONA Remedies shareholding pattern
| Holder | 13 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% | 69.00% |
| Foreign institutions | 1.04% | 1.84% | 2.25% | 3.63% |
| Domestic institutions | 3.65% | 6.76% | 7.02% | 12.90% |
| Non-institutions | 26.32% | 22.40% | 21.74% | 14.48% |
CORONA Remedies vs peers
The listed Pharma & Healthcare companies nearest to CORONA Remedies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,343 Cr | 32.1 | 13.8% |
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,294 Cr | 52.4 | — |
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,500 Cr | 66.8 | 24.8% |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,184 Cr | 43.9 | 16.9% |
| SUDEEPPHRMSudeep Pharma | ₹984.90 | +1.02% | — | ₹11,124 Cr | 66.2 | — |
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
Ask anything about CORONA Remedies
Pivot answers on the live chart with evidence you can check, and tests strategies against CORONA's own history. Try: “Why has CORONA moved over the last three months?” · “Backtest a 50-day moving-average crossover on CORONA over five years” · “Compare CORONA with MARKSANS on margins and valuation”
Frequently asked questions about CORONA Remedies
What is the share price of CORONA Remedies today?
CORONA Remedies (NSE: CORONA) last closed at ₹2,024.70 on 22 Oct 2026. Its 52-week high is ₹2,292.40 and its 52-week low is ₹1,336.60.
What is the market cap of CORONA Remedies?
CORONA Remedies' market capitalisation is ₹12,500 Cr (₹12,500 Cr) at the 22 Oct 2026 close, ranking 493rd among the NSE companies Pivot tracks.
What is the P/E ratio of CORONA Remedies?
CORONA Remedies trades at a trailing P/E of 66.8. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.4.
What is the ROE and ROCE of CORONA Remedies?
Return on equity was 24.8% in FY26 and return on capital employed was 31.5% in FY26 (consolidated figures).
Is CORONA Remedies a debt-free company?
No. CORONA Remedies' debt-to-equity ratio was 0.19 in FY26, with total debt of ₹0 Cr.
What were CORONA Remedies' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), CORONA Remedies reported revenue of ₹422 Cr, +21.9% year on year, and net profit of ₹60 Cr, +29.6% year on year.
What is the shareholding pattern of CORONA Remedies?
As of 30 Jun 2026: promoters 69.00%, foreign institutions 3.63%, domestic institutions 12.90%, non-institutions 14.48%.
Who are CORONA Remedies' competitors?
The listed Pharma & Healthcare companies closest to CORONA Remedies by market cap are Marksans Pharma, Concord Biotech, Rainbow Childrens Medicare, Sudeep Pharma, Metropolis Healthcare and Akums Drugs and Pharmaceuticals.
Is CORONA Remedies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out CORONA Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CORONA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text